TY - JOUR
T1 - Management strategies for female patients of reproductive potential with multiple sclerosis
T2 - An evidence-based review
AU - Coyle, Patricia K.
AU - Oh, Jiwon
AU - Magyari, Melinda
AU - Oreja-Guevara, Celia
AU - Houtchens, Maria
N1 - Funding Information:
Development of this manuscript was supported by Sanofi .
Funding Information:
Patricia K Coyle: Consulting fees from Accordant, Bayer, Biogen Idec, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva; research support from Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis. Jiwon Oh: Consulting or speaking fees (Biogen Idec, Celgene, EMD Serono, Genzyme, Novartis, Roche), Grant/research support (Biogen Idec, MS Society of Canada, National MS Society, Brain Canada). Melinda Magyari: Consulting and speaking fees (Biogen, Sanofi, Teva, Roche, Novartis, Merck) . Celia Oreja-Guevara: Consulting or speaking fees (Merck, Sanofi-Genzyme, Biogen Idec, Teva, Celgene, Novartis, Roche). Maria Houtchens: Consulting fees from Biogen, Genentech, Genzyme, Serono, Teva; research support from Genzyme , Biogen, Serono.
Publisher Copyright:
© 2019
PY - 2019/7
Y1 - 2019/7
N2 - Multiple sclerosis (MS)is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the disease itself has no impact on pregnancy, many women living with MS still question their ability to have children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize the importance of proper guidance from healthcare professionals, particularly neurologists. Management considerations are also complicated by the growing list of available treatment options. This review will summarize current evidence and expert opinion around the management of female MS patients of reproductive potential, from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS disease activity in the peripartum period.
AB - Multiple sclerosis (MS)is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the disease itself has no impact on pregnancy, many women living with MS still question their ability to have children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize the importance of proper guidance from healthcare professionals, particularly neurologists. Management considerations are also complicated by the growing list of available treatment options. This review will summarize current evidence and expert opinion around the management of female MS patients of reproductive potential, from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS disease activity in the peripartum period.
KW - Disease modifying therapy
KW - Family Planning
KW - Multiple sclerosis
KW - Postpartum
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85064699334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064699334&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2019.04.003
DO - 10.1016/j.msard.2019.04.003
M3 - Review article
C2 - 31030020
AN - SCOPUS:85064699334
SN - 2211-0348
VL - 32
SP - 54
EP - 63
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
ER -